Hansoh Pharma Wins NMPA Review Nod for New Targeted Lung Cancer Therapy

Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ) has provided an update.

Hansoh Pharmaceutical said China’s National Medical Products Administration has accepted a New Drug Application for Dalmelitinib Mesylate Tablets, an orally administered, highly selective c-MET tyrosine kinase inhibitor developed in-house. The drug is intended for use in combination with the company’s Aumolertinib Mesylate Tablets to treat locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer with MET amplification after prior EGFR TKI therapy.

The acceptance of the application marks a regulatory milestone for Hansoh in its push deeper into targeted lung cancer therapies and reinforces its position in China’s innovative oncology drug market. If ultimately approved, the combination regimen could expand the company’s oncology portfolio and offer a new treatment option for patients who have progressed on earlier-generation EGFR inhibitors, potentially strengthening its competitive standing among domestic cancer drug developers.

The most recent analyst rating on (HK:3692) stock is a Buy with a HK$44.00 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.

More about Hansoh Pharmaceutical Group Company Limited

Hansoh Pharmaceutical Group Company Limited is a China-based biopharmaceutical company focused on the research, development and commercialization of innovative medicines. Its portfolio includes targeted therapies such as tyrosine kinase inhibitors, with a particular emphasis on oncology treatments for conditions like non-small cell lung cancer in the domestic market.

Average Trading Volume: 7,756,297

Technical Sentiment Signal: Buy

Current Market Cap: HK$209.6B

Find detailed analytics on 3692 stock on TipRanks’ Stock Analysis page.